Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Wang M, Ramchandren R, Chen R, Karlin L, Chong G, Jurczak W, Wu KL, Bishton M, Collins GP, Eliadis P, Peyrade F, Lee Y, Eckert K, Neuenburg JK, Tam CS. Wang M, et al. Among authors: bishton m. J Hematol Oncol. 2021 Oct 30;14(1):179. doi: 10.1186/s13045-021-01188-x. J Hematol Oncol. 2021. PMID: 34717692 Free PMC article. Clinical Trial.
Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age.
Eyre TA, Martinez-Calle N, Hildyard C, Eyre DW, Plaschkes H, Griffith J, Wolf J, Fields P, Gunawan A, Oliver R, Djebbari F, Booth S, McMillan A, Fox CP, Bishton MJ, Collins GP, Hatton CSR. Eyre TA, et al. Among authors: bishton mj. J Intern Med. 2019 Jun;285(6):681-692. doi: 10.1111/joim.12889. Epub 2019 Apr 11. J Intern Med. 2019. PMID: 30811713 Free article.
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
Ng ZY, Bishton M, Ritchie D, Campbell R, Gilbertson M, Hill K, Ratnasingam S, Schwarer A, Manos K, Shorten S, Ng M, Nelson N, Xin L, De Mel Widanalage S, Sunny T, Purtill D, Poon M, Johnston A, Cochrane T, Lee HP, Hapgood G, Tam C, Opat S, Hawkes E, Seymour J, Cheah CY. Ng ZY, et al. Among authors: bishton m. Hematol Oncol. 2019 Aug;37(3):253-260. doi: 10.1002/hon.2618. Epub 2019 May 24. Hematol Oncol. 2019. PMID: 30983008
Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP.
Eyre TA, Martinez-Calle N, Hildyard C, Eyre DW, Plaschkes H, Griffith J, Wolf J, Fields PA, Gunawan A, Oliver R, Booth S, McMillan A, Fox CP, Bishton M, Collins GP, Hatton CSR. Eyre TA, et al. Among authors: bishton m. Br J Haematol. 2019 Aug;186(4):e94-e98. doi: 10.1111/bjh.15927. Epub 2019 Apr 24. Br J Haematol. 2019. PMID: 31020646 Free article. No abstract available.
Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.
Eyre TA, Kirkwood AA, Wolf J, Hildyard C, Mercer C, Plaschkes H, Griffith J, Fields P, Gunawan A, Oliver R, Booth S, Martinez-Calle N, McMillan A, Bishton M, Fox CP, Collins GP, Hatton CSR. Eyre TA, et al. Among authors: bishton m. Br J Haematol. 2019 Oct;187(2):185-194. doi: 10.1111/bjh.16070. Epub 2019 Jun 20. Br J Haematol. 2019. PMID: 31222719 Free article.
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
McCulloch R, Lewis D, Crosbie N, Eyre TA, Bolam S, Arasaretnam A, Creasey T, Goradia H, McMillan A, Dawi S, Harrison S, Miles O, Robinson A, Dutton D, Wilson MR, McKay P, Follows G, Phillips N, Patmore R, Lambert J, Bishton M, Osborne W, Johnston R, Kirkwood AA, Rule S. McCulloch R, et al. Among authors: bishton m. Br J Haematol. 2021 Apr;193(2):290-298. doi: 10.1111/bjh.17363. Epub 2021 Feb 23. Br J Haematol. 2021. PMID: 33620106 Free article.
Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP.
Eyre TA, Wilson W, Kirkwood AA, Wolf J, Hildyard C, Plaschkes H, Griffith J, Fields P, Gunawan A, Oliver R, Booth S, Kothari J, Fox CP, Martinez-Calle N, McMillan A, Bishton M, Collins GP, Hatton CSR. Eyre TA, et al. Among authors: bishton m. Blood Adv. 2021 Apr 27;5(8):2229-2236. doi: 10.1182/bloodadvances.2021004286. Blood Adv. 2021. PMID: 33890978 Free PMC article.
Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.
Martinez-Calle N, Kirkwood AA, Lamb M, Smith A, Khwaja J, Manos K, Shrubsole C, Gray N, Lewis K, Tivey A, Bishton MJ, Hawkes E, Ahearne MJ, Osborne W, Collins GP, Illidge T, Linton KM, Cwynarski K, Burton C, Fox CP. Martinez-Calle N, et al. Among authors: bishton mj. Adv Ther. 2021 Jul;38(7):3789-3802. doi: 10.1007/s12325-021-01764-0. Epub 2021 May 26. Adv Ther. 2021. PMID: 34037958 Free PMC article.
Histone deacetylase inhibitors in lymphoma and solid malignancies.
Rasheed W, Bishton M, Johnstone RW, Prince HM. Rasheed W, et al. Among authors: bishton m. Expert Rev Anticancer Ther. 2008 Mar;8(3):413-32. doi: 10.1586/14737140.8.3.413. Expert Rev Anticancer Ther. 2008. PMID: 18366289 Review.
77 results